Valuation
- Market cap
- 67,421,000
- Revenue TTM
- $0
- Net income TTM
- $-10,410,000
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.03
Trading
- Volume
- 54,200
- Avg volume
- 94,990
- Day's range
- $0.91 – $0.95
- Shares out
- 73,676,000
- Stochastic %K
- 43%
- Beta
- -0.19
- Analysts
- Strong Buy
- Price target
- $4.00
Company profile
Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Wilson's disease, Type 2 diabetes, age-related macular degeneration (AMD...
Show more
Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Wilson's disease, Type 2 diabetes, age-related macular degeneration (AMD), oncology, and epigenetic regulation, as well as Alzheimer's disease and Progeria. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Miami, Florida.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 786 396 6723
- Website
- https://telomirpharma.com
- Address
- 100 SE 2nd Street, Suite 2000 #1009, Miami, United States
Latest news
No headlines yet.
